https://www.yiliao.com/index.php?action=history&feed=atom&title=Ganitumab
Ganitumab - 版本历史
2026-04-18T18:22:38Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Ganitumab&diff=314619&oldid=prev
223.160.138.164：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-16T03:25:24Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[法列图珠单抗]]</strong>（<strong>[[Ganitumab]]</strong>，研发代码：<strong>[[AMG 479]]</strong>）是一种全人源化单克隆抗体（[[IgG1]]型），特异性靶向<strong>[[胰岛素样生长因子1受体]]</strong>（<strong>[[IGF-1R]]</strong>）。[[IGF-1R]]在多种恶性肿瘤的发生发展中起关键作用，通过激活下游[[PI3K/Akt]]和[[MAPK/ERK]]信号通路促进细胞增殖并抑制凋亡。[[法列图珠单抗]]通过与[[IGF-1R]]的高亲和力结合，竞争性阻断配体[[IGF-1]]和[[IGF-2]]的结合，从而诱导受体内吞及降解。尽管其在[[胰腺癌]]和[[尤文肉瘤]]等晚期临床试验中面临挑战，但其作为研究[[IGF]]通路抑制的标杆分子，在跨通路联合用药及精准靶向研究中仍具有重要价值。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[法列图珠单抗]]</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">[[Ganitumab]] / [[AMG 479]] · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[IGF-1R]]靶向抗体结合模型</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[IGF1R]] (CD221)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">3480([[IGF1R]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">5465</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P08069</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[全人源单克隆抗体]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[分子量]]</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约147kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">开发厂商</th><br />
<td style="padding: 12px; color: #0f172a;">[[Amgen]] (安进)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：IGF通路双重拦截</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[法列图珠单抗]]作为一种精准的生物制剂，通过以下多重生化效应发挥抗肿瘤作用：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>配体结合阻断：</strong>[[法列图珠单抗]]与[[IGF-1R]]的胞外结构域（[[ECD]]）结合，阻止配体[[IGF-1]]和[[IGF-2]]与受体接触。这直接切断了由生长因子诱导的酪氨酸激酶活化。</li><br />
<li style="margin-bottom: 12px;"><strong>受体下调作用：</strong>抗体与受体结合后，会触发[[IGF-1R]]从细胞膜表面向胞内发生[[内吞]]，并最终进入[[溶酶体]]降解。这一过程显著降低了细胞表面受体的密度，产生持久的抑制效应。</li><br />
<li style="margin-bottom: 12px;"><strong>信号级联级联：</strong>受体活性的丧失导致<strong>[[Akt]]</strong>和<strong>[[ERK1/2]]</strong>磷酸化水平下降。由于这些通路控制着细胞的[[凋亡逃逸]]和基因转录，[[法列图珠单抗]]能诱导肿瘤细胞发生生长停滞。</li><br />
<li style="margin-bottom: 12px;"><strong>ADCC效应潜在贡献：</strong>作为[[IgG1]]抗体，其[[Fc段]]具备通过激活[[NK细胞]]介导[[抗体依赖性细胞介导的细胞毒作用]]（[[ADCC]]）的潜力，进一步增强免疫打击。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床图谱：代表性研究矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">临床试验</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">研究背景/适应症</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">关键数据/结论</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[GAMMA研究]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">III期：联合[[吉西他滨]]治疗转移性胰腺腺癌。</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">未能显著提高[[OS]]；但在特定[[IGF]]生物标志物高表达亚组中观察到获益趋势。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[尤文肉瘤研究]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">II期：复发或难治性尤文肉瘤。</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">显示出临床缓解活性，客观缓解率（[[ORR]]）在少数特定患者中表现突出。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[乳腺癌探索]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">II期：联合内分泌治疗（[[依西美坦]]）。</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">旨在探索抑制 [[IGF-1R]] 是否能逆转 [[ER+]] 乳腺癌的获得性耐药。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：精准分层与代谢平衡</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[法列图珠单抗]]的后续应用重点转向了对患者分子特征的精细化筛选：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[生物标志物]]导向治疗：</strong>研究显示，循环[[IGF-1]]水平、[[IGFBP]]蛋白浓度及肿瘤组织中[[IGF-1R]]的磷酸化状态，是预测该药应答的关键指标。</li><br />
<li style="margin-bottom: 12px;"><strong>代偿性通路克服：</strong>[[IGF-1R]]抑制常引发[[胰岛素受体]]（[[IR]]）的代偿激活。目前的策略倾向于开发能同时靶向[[IGF-1R]]和[[IR-A]]的双抗体，或联合使用[[mTOR抑制剂]]。</li><br />
<li style="margin-bottom: 12px;"><strong>代谢风险管控：</strong>由于[[IGF-1R]]与[[胰岛素信号]]的结构相似性，需严密监测[[高血糖]]等代谢副作用，必要时需调整合并用药。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[IGF-1R]]：</strong>位于细胞膜上的酪氨酸激酶受体，其过表达与[[细胞恶性转化]]密切相关。</li><br />
<li style="margin-bottom: 8px;"><strong>[[尤文肉瘤]]：</strong>高度依赖 [[IGF]] 通路的儿童肿瘤，是 [[法列图珠单抗]] 的重要探索领域。</li><br />
<li style="margin-bottom: 8px;"><strong>[[吉西他滨]]：</strong>常与该抗体联用的标准化学疗法药物。</li><br />
<li style="margin-bottom: 8px;"><strong>[[内吞作用]]：</strong>抗体介导受体降解的核心细胞生物学过程。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Fuchs CS, et al. (2015).</strong> <em>A randomized, double-blind, placebo-controlled, phase 2 study of ganitumab or conatumumab in combination with gemcitabine as first-line treatment for metastatic adenocarcinoma of the pancreas.</em> <strong>[[Annals of Oncology]]</strong>. 26(5):921-927.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：该研究揭示了在非选择性人群中抑制IGF-1R的局限性，并强调了分选患者的重要性。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Pappo AS, et al. (2014).</strong> <em>Ganitumab (AMG 479) for patients with relapsed or refractory Ewing's sarcoma family of tumors or desmoplastic small round cell tumors: a multicenter, open-label, phase II study.</em> <strong>[[Journal of Clinical Oncology]]</strong>. 32(21):2221-2228.<br><br />
<span style="color: #475569;">[核心价值]：提供了法列图珠单抗在骨肉瘤领域的安全性和初步药效学数据。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[法列图珠单抗]] 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[IGF1R]]•[[Insulin Receptor]]•[[Akt]]•[[IRS1]]•[[mTOR]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[吉西他滨]]•[[依西美坦]]•[[替莫唑胺]]•[[西妥昔单抗]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Amgen]]•[[FDA]]•[[St. Jude Children's Research Hospital]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td><br />
<td style="padding: 10px 15px; color: #334155;">[[IGF-1R与免疫检查点抑制剂联用]]•[[针对尤文肉瘤的ADC药物演进]]•[[新型双特异性IGF/IR抗体研发]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.164